Piper Sandler Reiterates Overweight on Century Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Century Therapeutics (NASDAQ:IPSC) but lowered the price target from $10 to $9.
April 12, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler reaffirms Overweight rating on Century Therapeutics but reduces price target to $9.
The reiteration of the Overweight rating suggests a positive outlook on the stock by Piper Sandler, indicating confidence in the company's fundamentals or growth prospects. However, the reduction in the price target from $10 to $9, while still implying a bullish stance, suggests a slight adjustment in expectations regarding the stock's future price performance. This could be due to a variety of factors such as market conditions, recent company performance, or revised forecasts. Investors might view this adjustment as a minor recalibration of expectations rather than a significant change in sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100